Section Arrow
Quote
APLS.NASDAQ
- Apellis Pharmaceuticals
Quotes are at least 15-min delayed:2025/09/04 10:13 EDT
Regular Hours
Last
 27.94
+0.14 (+0.50%)
Day High 
27.965 
Prev. Close
27.8 
1-M High
28.87 
Volume 
156.35K 
Bid
27.94
Ask
27.97
Day Low
27.26 
Open
27.5 
1-M Low
22.89 
Market Cap 
3.51B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 27.74 
20-SMA 26.68 
50-SMA 22.38 
52-W High 41.94 
52-W Low 16.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.83/-1.20
Enterprise Value
3.97B
Balance Sheet
Book Value Per Share
1.24
Cash Flow
Cash Flow Yield
0.00
Income Statement
Total Revenue
781.37M
Operating Revenue Per Share
2.16
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADAPAdaptimmune Therapeutics plc0.0485-0.0041-7.79%-- 
PPBTPurple Biotech Ltd0.8747-0.5453-38.40%0PE
ETHZETHZilla Corporation2.355-0.165-6.55%-- 
SGMOSangamo Therapeutics0.4957-0.0383-7.17%-- 
RXRXRecursion Pharmaceuticals4.53-0.1-2.16%-- 
Quotes are at least 15-min delayed：2025/09/04 10:13 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.